Amundi doubles down on AI megacaps and pivots hard into oil

The biggest buy is unambiguous: TotalEnergies goes from zero to a 5.14% stake, a $18.9B line that instantly makes it one of Amundi’s core holdings. That’s not a tactical trade; it’s a statement that multi-year free cash flow from integrated oil & gas is cheap relative to both global equities and to US majors already in the book.

On tech, Amundi is no longer just riding the AI trade; it is deliberately concentrating it into the control points. They added aggressively to Microsoft (+30.8% shares), Apple (+23.2%), Alphabet (both share classes up 12.7–22.9%), Amazon (+14.1%) and NVIDIA (+10.4%), while still showing huge embedded gains, especially in NVIDIA and Alphabet.

The more interesting shift is underneath the headlines: a notable push into AI “plumbing.”

• Lam Research: shares up 23.7%, reinforcing wafer fabrication gear as a structural bottleneck.
• KLA: +37.0% shares, another process-control winner in the same capex cycle.
• Micron: +19.7%, leaning into HBM and memory scarcity as AI models scale.
• GE Vernova: +256.6%, and GE Aerospace +135.2% — a sizable vote that electrification and aerospace capex will run alongside compute demand.

Healthcare isn’t ignored either. A new $3.03B AstraZeneca line plus adds to Eli Lilly, Johnson & Johnson, Merck and Gilead suggest Amundi wants durable, innovation-driven earnings to sit opposite its more cyclical energy and industrials exposure.

The trims this quarter look more like housekeeping than a regime change, but the pattern is clear: raise cash from crowded winners and stale defensives to fund a fresh oil-and-AI core.

On the growth side, the only meaningful semiconductor reduction is AMD, with shares cut 13.6%. Given AMD still sits on a large gain versus cost, this looks like a relative-value rotation from a highly sentiment-driven AI name into NVIDIA and the equipment/memory complex, not a repudiation of the chip cycle.

Consumer and healthcare cuts are more blunt.

• Home Depot: -13.6% shares and sitting below cost, suggesting waning patience with rate-sensitive US housing exposure.
• Walmart: -9.6% shares despite strong gains, reallocating away from low-vol, low-growth staples-like retail.
• Coca-Cola: a modest 4.2% trim, consistent with reducing bond-proxy beverages to finance higher-return ideas.
• UnitedHealth: -13.3% shares and underwater versus cost; they’re clearly less willing to ride policy and utilization noise in managed care when better risk/reward exists in big pharma and AI.

Netflix is only lightly reduced (down 1.1% shares), more a liquidity source than a view change. The common thread: they are shedding incremental exposure to US consumer defensives and idiosyncratic policy risk to double down on areas where they believe earnings power is both misunderstood and scalable.

Even after this quarter, technology still dominates the book at 52.1% of the disclosed portfolio, but that’s down meaningfully from an estimated 56.92%. Amundi hasn’t abandoned tech at all — it has sharpened it: more in AI platforms and semis infrastructure, less in peripheral or duplicative exposure.

The real story is energy. Sector weight jumps from 3.90% to 12.21%, driven by the TotalEnergies build and top-ups in Exxon and Chevron. That converts energy from a satellite to a core macro bet: higher-for-longer demand, constrained supply discipline, and robust buyback/dividend support.

Consumer discretionary steps down from 13.08% to 10.95%, with trims in Home Depot, Walmart and a tiny cut in Netflix partly offset by adds to Amazon, Costco and TJX. This is a rotation away from rate- and low-income-exposed US consumption toward global e-commerce and value-oriented retail.

Financials drift slightly lower (4.77% to 4.15%) despite share increases in Bank of America, JPMorgan, Deutsche Bank, Goldman Sachs and Citigroup, suggesting relative underperformance rather than conviction loss. Healthcare, at 8.66% versus 8.67%, is steady in aggregate but internally shifting from managed care into pharma/biotech, while industrials and the “payments” names Visa and Mastercard quietly grow as leveraged plays on global nominal GDP and transaction volumes.

Put together, Amundi’s 2026-Q1 moves sketch a manager leaning into volatility rather than hiding from it. After a -9.04% quarter, they are increasing concentration in AI’s structural winners and building a new energy pillar instead of rotating into cash or low-beta sectors.

The thesis looks straightforward: AI remains a multi-year capex and profit cycle, but leadership will consolidate around a handful of platforms (Microsoft, Apple, Alphabet, Amazon, NVIDIA) and the hardware choke points (semicap, memory, analog). At the same time, energy and select industrials offer old-economy cash flows that can keep compounding even if multiples compress elsewhere.

Healthcare and payments provide the ballast. AstraZeneca, Eli Lilly, Merck, Gilead, Johnson & Johnson and AbbVie give exposure to pipeline-driven earnings rather than pure macro, while Visa, Mastercard and Berkshire Hathaway function as diversified plays on financial and real-economy throughput.

For observers, the message is that Amundi still wants cyclicality and duration — but only where it controls something critical: compute, energy molecules, grid infrastructure, data, or drug IP. Expect future quarters to keep bleeding capital out of generic defensives and peripheral cyclicals, and into whichever businesses sit at the next bottleneck in the AI, energy and industrial-capex stack.